NCT07206095 Integrative Diagnosis for SCD and Other RADs
| NCT ID | NCT07206095 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Condition | Sickle Cell Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-11-13 |
| Primary Completion | 2025-05-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2020-11-13 with a primary completion date of 2025-05-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
Eligibility Criteria
Inclusion Criteria: * Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia: * Sickle cell disease * Thalassemic syndromes * Congenital dyserythropoietic anemia * Enzymopathy * Unstable Hemoblogin / Altered oxygen affinity * Hereditary stomatocytosis * Hereditary pyropoikilocytosis * Hereditary spherocytosis with severe anemia (\<8 g/dL) or inconclusive diagnosis: * Patient with chronic hemolytic anemia and red cell smear compatible, but with: * EMA binding test: inconclusive or negative * Genetic testing: no definitive diagnosis (VUS or no findings) * Not transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included. Exclusion Criteria: * Carrier traits in autosomal recessive hereditary anemias
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07206095 clinical trial?
This trial is open to participants of all sexes, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07206095 currently recruiting?
Yes, NCT07206095 is actively recruiting participants. Contact the research team at mar.manu@vhir.org for enrollment information.
Where is the NCT07206095 trial being conducted?
This trial is being conducted at Barcelona, Spain, Barcelona, Spain, Esplugues de Llobregat, Spain, Granollers, Spain and 5 additional locations.
Who is sponsoring the NCT07206095 clinical trial?
NCT07206095 is sponsored by Hospital Universitari Vall d'Hebron Research Institute. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.